Abstract
Desferoxamine has been suggested to improve erythopoiesis in end-stage renal failure also independently by its aluminium - chelating effect. We yet proved the effect of DFO on erythroid precursor proliferation. In order to verify whether there may be a synergic action of DFO and r-HuEpo, we enrolled 11 patients treated by hemodialysis, free from other chronic or hematological diseases. All had a negative DFO test, very low serum Al levels, below 20 mcg/l, ferritin > 100 ng% and iPTH <200 pg/l. Samples were drawn for a basal erythroid precursors (Burst Forming Unit-Erythroid, BFU-E) evaluation: after isolation by Ficoll - Hypaque a 14-day incubation was carried out with: A) r- HuEpo 3u/ml: B) r-HuEpo 30 u/l and C) r-HuEpo 30 u/ml + DFO 167 mcg/ml. Patients then received DFO 5 mg/kg infused during the last hour of each dialysis session for 12 weeks. New BFU-E evaluations were set up after 2, 6 and 12 weeks of treatment. At the same points we also evaluated hemoglobin, ferritin transferrin, retycolocites, hypochronic erythrocites, soluble transferrin receptor and serum erythroprotein. As expected, high-dose r- HuEpo showed a higher proliferation versus low-dose r-HuEpo during all the phases of the study; interestingly, culture C yet basally showed an increased proliferation respect to cultures B: the same feature was found after 2, 6 and 12 weeks. Moreover, all studied cultures showed an increased proliferation after DFO therapy. Hemoglobin levels showed a slightly increase, such as reticolocites and sTR, while ferritin decreased. Thus, DFO increases eryhtroid precursors proliferation in chronic renal failure patients and shows a synergic effect with r-HuEpo: further investigation is needed, to ascertain whether such an effect may have clinical application.
| Original language | Italian |
|---|---|
| Pages (from-to) | 241-247 |
| Number of pages | 7 |
| Journal | Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia |
| Volume | 15 |
| Issue number | 5 |
| Publication status | Published - 1998 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Effetto sinergico di desferoxamina (DFO) ed eritropoietina sulla proliferazione dei precursori eritroidi nell'uremia cronica. / Aucella, F.; Scalzulli, P.; Musto, P.; Prencipe, M.; Valente, G. L.; Vigilante, M.; Carotenuto, M.; Stallone, C.
In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, Vol. 15, No. 5, 1998, p. 241-247.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effetto sinergico di desferoxamina (DFO) ed eritropoietina sulla proliferazione dei precursori eritroidi nell'uremia cronica
AU - Aucella, F.
AU - Scalzulli, P.
AU - Musto, P.
AU - Prencipe, M.
AU - Valente, G. L.
AU - Vigilante, M.
AU - Carotenuto, M.
AU - Stallone, C.
PY - 1998
Y1 - 1998
N2 - Desferoxamine has been suggested to improve erythopoiesis in end-stage renal failure also independently by its aluminium - chelating effect. We yet proved the effect of DFO on erythroid precursor proliferation. In order to verify whether there may be a synergic action of DFO and r-HuEpo, we enrolled 11 patients treated by hemodialysis, free from other chronic or hematological diseases. All had a negative DFO test, very low serum Al levels, below 20 mcg/l, ferritin > 100 ng% and iPTH <200 pg/l. Samples were drawn for a basal erythroid precursors (Burst Forming Unit-Erythroid, BFU-E) evaluation: after isolation by Ficoll - Hypaque a 14-day incubation was carried out with: A) r- HuEpo 3u/ml: B) r-HuEpo 30 u/l and C) r-HuEpo 30 u/ml + DFO 167 mcg/ml. Patients then received DFO 5 mg/kg infused during the last hour of each dialysis session for 12 weeks. New BFU-E evaluations were set up after 2, 6 and 12 weeks of treatment. At the same points we also evaluated hemoglobin, ferritin transferrin, retycolocites, hypochronic erythrocites, soluble transferrin receptor and serum erythroprotein. As expected, high-dose r- HuEpo showed a higher proliferation versus low-dose r-HuEpo during all the phases of the study; interestingly, culture C yet basally showed an increased proliferation respect to cultures B: the same feature was found after 2, 6 and 12 weeks. Moreover, all studied cultures showed an increased proliferation after DFO therapy. Hemoglobin levels showed a slightly increase, such as reticolocites and sTR, while ferritin decreased. Thus, DFO increases eryhtroid precursors proliferation in chronic renal failure patients and shows a synergic effect with r-HuEpo: further investigation is needed, to ascertain whether such an effect may have clinical application.
AB - Desferoxamine has been suggested to improve erythopoiesis in end-stage renal failure also independently by its aluminium - chelating effect. We yet proved the effect of DFO on erythroid precursor proliferation. In order to verify whether there may be a synergic action of DFO and r-HuEpo, we enrolled 11 patients treated by hemodialysis, free from other chronic or hematological diseases. All had a negative DFO test, very low serum Al levels, below 20 mcg/l, ferritin > 100 ng% and iPTH <200 pg/l. Samples were drawn for a basal erythroid precursors (Burst Forming Unit-Erythroid, BFU-E) evaluation: after isolation by Ficoll - Hypaque a 14-day incubation was carried out with: A) r- HuEpo 3u/ml: B) r-HuEpo 30 u/l and C) r-HuEpo 30 u/ml + DFO 167 mcg/ml. Patients then received DFO 5 mg/kg infused during the last hour of each dialysis session for 12 weeks. New BFU-E evaluations were set up after 2, 6 and 12 weeks of treatment. At the same points we also evaluated hemoglobin, ferritin transferrin, retycolocites, hypochronic erythrocites, soluble transferrin receptor and serum erythroprotein. As expected, high-dose r- HuEpo showed a higher proliferation versus low-dose r-HuEpo during all the phases of the study; interestingly, culture C yet basally showed an increased proliferation respect to cultures B: the same feature was found after 2, 6 and 12 weeks. Moreover, all studied cultures showed an increased proliferation after DFO therapy. Hemoglobin levels showed a slightly increase, such as reticolocites and sTR, while ferritin decreased. Thus, DFO increases eryhtroid precursors proliferation in chronic renal failure patients and shows a synergic effect with r-HuEpo: further investigation is needed, to ascertain whether such an effect may have clinical application.
KW - Chronic uremia
KW - Desferoxamine
KW - Erythroid precursors
KW - Erythropoiesis
UR - http://www.scopus.com/inward/record.url?scp=0031737338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031737338&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0031737338
VL - 15
SP - 241
EP - 247
JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
SN - 0393-5590
IS - 5
ER -